 |
 |
 |
 |
 |
 |
 |
 |
 | |||||
|
|||||
| |||||
| NanoCrystal® Technology | |
| Case Study 1 | Differentiation through enhanced patient acceptability - Rapamune® Oral Tablet Formulation |
| Case Study 2 | Enhanced patient acceptability - Creating a branded opportunity |
| Oral Controlled Release | |
| Case Study 1 | Once Daily, novel dual release morphine sulphate |
| Case Study 2 | Once daily, night-time dosed, anti-hypertensive to minimize risk of early-morning cardiovascular events |